Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men

S. C. Cottin*, A. Alsaleh, T. A.B. Sanders, W. L. Hall

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aims

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil are postulated to have favourable effects on platelet, endothelial and vascular function. We investigated whether EPA has differential effects on in vivo platelet aggregation and other markers of cardiovascular risk compared to DHA.

Methods and Results

Following a 2 wk run-in taking encapsulated refined olive oil, 48 healthy young men were randomly allocated using a parallel design to receive EPA-rich (3.1 g EPA/d) or DHA-rich (2.9 g DHA/d) triglyceride concentrates or refined olive oil (placebo), for a total supplementary lipid intake of 5 g/d. The specified primary outcome was change in platelet monocyte aggregates (PMA); secondary outcomes were capillary density, augmentation index, digital pulse volume measurements, 24 h ambulatory BP, plasma 8-isoprostanes-F2α. Changes in the proportions of DHA and EPA in erythrocytes and non-esterified fatty acid composition indicated compliance to the intervention. There was no significant treatment effect on PMA (P = 0.382); mean changes (%) (95% CI) were placebo −0.5 (−2.0, 1.04), EPA 0.4 (−0.8, 1.6), DHA 0.3 (−1.5, 2.0). R-QUICKI, an index of insulin sensitivity, was greater following EPA compared to placebo (P < 0.05). No other significant differences were noted.

Conclusion

Neither EPA- nor DHA-rich fish oil supplementation influence platelet-monocyte aggregation or several markers of vascular function after 6 wk in healthy young males. This trial was registered at clinicaltrials.gov as NCT01735357.

Original languageEnglish
Pages (from-to)743-751
Number of pages9
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume26
Issue number8
Early online date15 Mar 2016
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Fingerprint

Blood Vessels
Monocytes
8-epi-prostaglandin F2alpha
Blood Platelets
Fish Oils
Placebos
Acids
Platelet Aggregation
Triglycerides
Fatty Acids
Lipids
Olive Oil
Therapeutics

Cite this

@article{1c89f6f4914a44bc92894ae4a1c823a8,
title = "Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men",
abstract = "Background and AimsEicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil are postulated to have favourable effects on platelet, endothelial and vascular function. We investigated whether EPA has differential effects on in vivo platelet aggregation and other markers of cardiovascular risk compared to DHA.Methods and ResultsFollowing a 2 wk run-in taking encapsulated refined olive oil, 48 healthy young men were randomly allocated using a parallel design to receive EPA-rich (3.1 g EPA/d) or DHA-rich (2.9 g DHA/d) triglyceride concentrates or refined olive oil (placebo), for a total supplementary lipid intake of 5 g/d. The specified primary outcome was change in platelet monocyte aggregates (PMA); secondary outcomes were capillary density, augmentation index, digital pulse volume measurements, 24 h ambulatory BP, plasma 8-isoprostanes-F2α. Changes in the proportions of DHA and EPA in erythrocytes and non-esterified fatty acid composition indicated compliance to the intervention. There was no significant treatment effect on PMA (P = 0.382); mean changes ({\%}) (95{\%} CI) were placebo −0.5 (−2.0, 1.04), EPA 0.4 (−0.8, 1.6), DHA 0.3 (−1.5, 2.0). R-QUICKI, an index of insulin sensitivity, was greater following EPA compared to placebo (P < 0.05). No other significant differences were noted.ConclusionNeither EPA- nor DHA-rich fish oil supplementation influence platelet-monocyte aggregation or several markers of vascular function after 6 wk in healthy young males. This trial was registered at clinicaltrials.gov as NCT01735357.",
author = "Cottin, {S. C.} and A. Alsaleh and Sanders, {T. A.B.} and Hall, {W. L.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.numecd.2016.03.004",
language = "English",
volume = "26",
pages = "743--751",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier",
number = "8",

}

Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men. / Cottin, S. C.; Alsaleh, A.; Sanders, T. A.B.; Hall, W. L.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 26, No. 8, 01.08.2016, p. 743-751.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men

AU - Cottin, S. C.

AU - Alsaleh, A.

AU - Sanders, T. A.B.

AU - Hall, W. L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background and AimsEicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil are postulated to have favourable effects on platelet, endothelial and vascular function. We investigated whether EPA has differential effects on in vivo platelet aggregation and other markers of cardiovascular risk compared to DHA.Methods and ResultsFollowing a 2 wk run-in taking encapsulated refined olive oil, 48 healthy young men were randomly allocated using a parallel design to receive EPA-rich (3.1 g EPA/d) or DHA-rich (2.9 g DHA/d) triglyceride concentrates or refined olive oil (placebo), for a total supplementary lipid intake of 5 g/d. The specified primary outcome was change in platelet monocyte aggregates (PMA); secondary outcomes were capillary density, augmentation index, digital pulse volume measurements, 24 h ambulatory BP, plasma 8-isoprostanes-F2α. Changes in the proportions of DHA and EPA in erythrocytes and non-esterified fatty acid composition indicated compliance to the intervention. There was no significant treatment effect on PMA (P = 0.382); mean changes (%) (95% CI) were placebo −0.5 (−2.0, 1.04), EPA 0.4 (−0.8, 1.6), DHA 0.3 (−1.5, 2.0). R-QUICKI, an index of insulin sensitivity, was greater following EPA compared to placebo (P < 0.05). No other significant differences were noted.ConclusionNeither EPA- nor DHA-rich fish oil supplementation influence platelet-monocyte aggregation or several markers of vascular function after 6 wk in healthy young males. This trial was registered at clinicaltrials.gov as NCT01735357.

AB - Background and AimsEicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil are postulated to have favourable effects on platelet, endothelial and vascular function. We investigated whether EPA has differential effects on in vivo platelet aggregation and other markers of cardiovascular risk compared to DHA.Methods and ResultsFollowing a 2 wk run-in taking encapsulated refined olive oil, 48 healthy young men were randomly allocated using a parallel design to receive EPA-rich (3.1 g EPA/d) or DHA-rich (2.9 g DHA/d) triglyceride concentrates or refined olive oil (placebo), for a total supplementary lipid intake of 5 g/d. The specified primary outcome was change in platelet monocyte aggregates (PMA); secondary outcomes were capillary density, augmentation index, digital pulse volume measurements, 24 h ambulatory BP, plasma 8-isoprostanes-F2α. Changes in the proportions of DHA and EPA in erythrocytes and non-esterified fatty acid composition indicated compliance to the intervention. There was no significant treatment effect on PMA (P = 0.382); mean changes (%) (95% CI) were placebo −0.5 (−2.0, 1.04), EPA 0.4 (−0.8, 1.6), DHA 0.3 (−1.5, 2.0). R-QUICKI, an index of insulin sensitivity, was greater following EPA compared to placebo (P < 0.05). No other significant differences were noted.ConclusionNeither EPA- nor DHA-rich fish oil supplementation influence platelet-monocyte aggregation or several markers of vascular function after 6 wk in healthy young males. This trial was registered at clinicaltrials.gov as NCT01735357.

U2 - 10.1016/j.numecd.2016.03.004

DO - 10.1016/j.numecd.2016.03.004

M3 - Article

C2 - 27105870

AN - SCOPUS:84963858159

VL - 26

SP - 743

EP - 751

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 8

ER -